CORBUS PHARMACEUTICALS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma ® | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Emerging growth company ☐ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charte ...

CORBUS PHARMACEUTICALS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma ® | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

CORBUS PHARMACEUTICALS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma ® | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - The company's cash position has significantly strengthened, now standing at approximately $127 million, providing a cash runway into early 2024 based on current expectations [7][20]. - The expected operational burn rate is projected to be around $10 million per quarter, down from $21 million in the previous quarter, due to completed pivotal studies and workforce reductions [26]. Business Line Data and Key Metrics Changes - The Phase 3 DETERMINE study for lenabasum in dermatomyositis is progressing on schedule, with all subjects having completed their week 28 visits, and topline results expected in the second quarter of 2021 [9][10]. - A discontinuation rate of around 8% was reported in the dermatomyositis study, which is lower than anticipated, with approximately 166 patients completing the week 28 visit [28]. Market Data and Key Metrics Changes - The approval of Roche's Actemra for treating interstitial lung disease in systemic sclerosis, despite failing primary efficacy endpoints, has prompted the company to reassess its own data regarding lenabasum [10][30]. Company Strategy and Development Direction - The company aims to maximize the value of lenabasum, advance its internal pipeline into clinical testing in 2022, and engage with potential partners to expand its pipeline [5][6]. - There is a focus on diversifying the pipeline beyond the endocannabinoid system and autoimmune diseases, seeking best-in-class compounds supported by scientific data [18]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of lenabasum and the internal pipeline, anticipating significant data inflection points in the near future [5][21]. - The company is committed to advancing its pipeline and bringing in external assets that complement existing capabilities [21]. Other Important Information - The NIH-sponsored Phase 2 study of lenabasum in Systemic Lupus Erythematosus is nearing completion of enrollment, with topline data expected in the second half of the year [12]. - The company is exploring the implications of recent findings in forced vital capacity related to lenabasum, particularly in the context of systemic sclerosis [10][30]. Q&A Session Summary Question: Comfort level in selecting candidates for CB1 and CB2 programs - Management expressed confidence in reaching a desirable profile for CB1 inverse agonists, with promising compounds identified, while the CB2 agonist program is slightly behind but also shows potential [24][25]. Question: Clarification on cash runway and operational expenses - The CFO explained that the reduced operational expenses are due to completed studies and workforce reductions, projecting a $10 million burn rate going forward [26]. Question: Details on the dermatomyositis study and patient enrollment - Approximately 166 patients completed the week 28 visit, with an 8% discontinuation rate, and 90% of eligible subjects have enrolled in the open-label extension [28]. Question: Next steps following Actemra's approval - Management indicated that the next update on potential pathways would depend on the dermatomyositis study data, with timelines expected in the second half of the year [30][31].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________. COMMISSION FILE NUMBER: 001-37348 | --- | --- | --- | |---------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - The company underwent a significant restructuring to reduce costs and extend its cash runway to $82 million, projected to last until mid-2022 [34] - The company reported disappointing top-line data from its Phase 3 study in systemic sclerosis and Phase 2b study in cystic fibrosis, with lenabasum not meeting its primary endpoints [8][16] Business Line Data and Key Metrics Changes - The Phase 3 study of lenabasum in systemic sclerosis did not meet its primary endpoint, but post-hoc analyses suggested potential clinical activity in patients on established immunosuppressants [16][20] - In the Phase 2b study for cystic fibrosis, lenabasum treatment was associated with a maximum reduction of pulmonary exacerbations by up to 62% in specific patient subsets [24] Market Data and Key Metrics Changes - The dermatomyositis market presents a significant opportunity with approximately 30,000 patients in the U.S. and a clear unmet need [11] - The company plans to shorten the duration of the Phase 3 DETERMINE study from one year to 28 weeks to align with competitive studies and accelerate topline data readouts [12][28] Company Strategy and Development Direction - The company aims to rebuild shareholder value through three concepts: demonstrating lenabasum's clinical activity, focusing on dermatomyositis as a value driver, and leveraging its pipeline beyond lenabasum [9][11][13] - The company is evaluating options for expanding its pipeline with external assets that complement its current capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in recent trials but remains optimistic about the potential of lenabasum in specific indications [8][10] - The company is committed to collaborating with experts in systemic sclerosis and cystic fibrosis to explore future study designs and regulatory pathways [36][60] Other Important Information - The company has a promising preclinical program involving a novel family of CB2 agonists that may inhibit tumor cell growth [32] - The Chief Operating Officer has resigned, which may impact the company's leadership dynamics [35] Q&A Session Summary Question: Rationale behind shortening the dermatomyositis study - Management noted that the study duration was adjusted based on competitive landscape and preliminary data indicating that most improvements occur within the first six months [40][42] Question: Limitations observed with CRB-4001 - Management identified formulation challenges and concerns regarding blood-brain barrier penetration as key issues with CRB-4001, leading to a shift in focus to more promising compounds [46][48] Question: Regulatory path for systemic sclerosis trial - Management clarified that the recent Phase 3 study is not adequate for regulatory approval, and further studies will be necessary to support a new application [50][51] Question: Feedback from the cystic fibrosis community - Management indicated ongoing discussions with the cystic fibrosis community but emphasized that the failure to meet the primary endpoint limits the current trial's utility for approval [52] Question: Future development candidates for CB1 inverse agonists - Management plans to prioritize one promising compound for clinical development while keeping options open for others based on preclinical data [61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 ...

Pioneering transformative medicines that target the endocannabinoid system RESOLVE-1 Phase 3 Study of Lenabasum in Systemic Sclerosis NASDAQ: CRBP @corbuspharma © 2019 Corbus Pharmaceuticals Holdings, Inc. | R&D Day June 21, 2019 www.corbuspharma.com © 2020 Corbus Pharmaceuticals Holdings, Inc. Systemic Sclerosis: The Unmet Need 2 © 2020 Corbus Pharmaceuticals Holdings, Inc. 09 Nov 2020 © 2019 Corbus Pharmaceuticals Holdings, Inc. | R&D Day June 21, 2019 Systemic sclerosis is a rare, debilitating and life-t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 ...